Clinical Trials
Spectrum advances anticancer agent toward registration, plans 2006 phase 3 study start
Published in Medical Letter on the CDC and FDA, April 12th, 2006
EOquin has previously undergone a number of clinical studies in Europe, including a successful phase 2, marker lesion study, which showed good tolerance and a durable, high complete response rate (67%).
A successful pre-IND and end of phase 2 meeting with the FDA, in January 2006, in which the development strategy, including the phase 3 design and objectives, were discussed, preceded this IND filing. The U.S. clinical study program will initiate...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Contrast Media
Deaths attributed to X-ray contrast media - Splenectomy
Post-splenectomy infection risk called an important health problem - Stroke
Reimbursement practices and public health efforts critical to improve stroke reporting, outcomes - Adverse Drug Reaction
Chiron recalls, withdraws Morupar MMR vaccine from Italian and developing world markets - Avian Influenza
Recombinomics urges release of H5N1 avian influenza sequences from WHO private database - Avian Influenza
U.S. Department of Health orders 1.75 million more courses of anti-viral zanamivir Relenza - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
